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Although transgene-based reporter gene assays
have been used to discover small molecules target-
ing expression of cancer-driving genes, the success
is limited due to the fact that reporter gene expres-
sion regulated by incomplete cis-acting elements
and foreign epigenetic environments does not faith-
fully reproduce chemical responses of endogenous
genes. Here, we present an internal ribosome entry
site-based strategy for bicistronically co-expressing
reporter genes with an endogenous gene in the
native gene locus, yielding an in situ reporter assay
closely mimicking endogenous gene expression
without disintegrating its function. This strategy
combines the CRISPR-Cas9-mediated genome-edit-
ing tool with the recombinase-mediated cassette-
exchange technology, and allows for rapid develop-
ment of orthogonal assays for excluding false hits
generated from primary screens. We validated this
strategy by developing a screening platform for
identifying compounds targeting oncogenic eIF4E,
and demonstrated that the novel reporter assays
are powerful in searching for transcription-targeted
lead compounds with high confidence.
INTRODUCTION
Aberrant gene expression is a hallmark of cancer, and often
drives growth, survival, and metastasis of malignant cells. Since
cancer cells frequently develop dependency on altered expres-
sion of cancer-driving genes, it is generally believed that thera-
peutic agents capable of rectifying these abnormalities are
promising in curing this deadly disease (Yan and Paul, 2013).
The eukaryotic translation initiation factor 4E (eIF4E), for
instance, is frequently overexpressed in human cancer and
contributes to cancer development by selectively promoting
translation of genes essential for cancer cell growth and survivalChemistry & Biology 22,(e.g., c-myc, VEGF, BCL2) (Graff et al., 2008). As eIF4E hyperac-
tivity is the convergence point of common oncogenic pathways,
downregulation of EIF4E expression could be an ideal strategy
for therapeutic intervention in cancer (Hsieh and Ruggero,
2010; Bitterman and Polunovsky, 2012). Indeed, an EIF4E-spe-
cific antisense oligonucleotide was shown to inhibit growth of a
wide range of cancer cells and has entered clinical trials (Graff
et al., 2007).
However, aberrant gene expression, which is often a conse-
quence of dysregulated transcription, is traditionally considered
an ‘‘undruggable’’ target (Yan and Paul, 2013), mainly due to the
lack of reliable high-throughput screening (HTS) assays that can
be employed to search for small molecules regulatory for gene
expression. Reporter assays whereby bioluminescent reporter
genes (e.g., firefly luciferase, FLuc) are typically fused to a cloned
promoter and stably integrated into a random genomic location
provide a rapid, convenient, and cost-efficient means to monitor
alternations in gene expression upon chemical treatments, and
have been successfully used in high-throughput drug discovery
(Rapisarda et al., 2002; Nakahara et al., 2007). Given that
randomly integrated reporters are often epigenetically silenced
by flanking condensed chromatin (Yan and Boyd, 2006), we
recently developed a technology that can integrate a reporter
gene into a predefined permissive genomic location through ho-
mologous recombination mediated by the Flp recombinase (Yan
et al., 2004; Nair et al., 2008). Despite these successes, current
reporter assays are mainly based on cloned, transgenic pro-
moters, and are often unreliable in reproducing responses of
endogenous genes to chemical treatments due to twomajor lim-
itations. First, cloned promoters often lack essential cis-acting
elements far-removed from transcription start sites (TSS) (e.g.,
enhancers). While they may localize more than 40 kb apart
from TSS, these distal cis-regulatory elements interact with
proximal promoters through DNA looping, strongly influencing
activities of the latter to drive gene expression (Pennacchio
et al., 2013; Levine et al., 2014). Consequently, drug screens
based on cloned promoters would miss a substantial number
of small molecules regulatory for distal cis-elements. Second,
transgenic promoters are integrated into genomic locations
divergent from their native counterparts. Whereas a previously
naked (non-chromatinized) transgenic promoter is assembled957–964, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 957
Figure 1. Co-expression of a Bicistronic In Situ Reporter with an
Endogenous Gene
Schematic showing co-expression of a bicistronic in situ reporter with an
endogenous gene under the control of the native transcriptional regulatory
machinery. GTF, general transcription factors; IRES, internal ribosome entry
site; Luc, luciferase gene; Pol II, RNA polymerase II; TF, transcription factors.into chromatin structurally similar to the integration site upon
integration (Yan and Boyd, 2006), the foreign chromatin envi-
ronment could alter the reporter gene expression in a manner
atypical of the endogenous gene. Accordingly, screens based
on transgenic promoters would yield high rates of false positives
while agents targeting epigenetic mechanisms for regulating
endogenous gene expression would be missed. Although recent
studies attempting to insert reporter genes into sites immediately
downstream of the endogenous promoter (Lyssiotis et al., 2009)
partly address these concerns, the close proximity of a large size
of exogenous DNA to TSS results in not only disintegration of the
endogenous gene, but also changes in transcription initiation
and/or enhancer looping essential for gene transcription (Pen-
nacchio et al., 2013).
To address these limitations, we employed emerging genome-
editing tools to develop anovel reporter assaywhereby a reporter
gene was engineered into a genomic site immediately down-
stream of the coding region of an endogenous gene, and co-
expressed bicistronically with the endogenous gene as a single
transcript under the control of the native transcriptional regula-
tory machinery. We demonstrated that this bicistronic in situ re-
porter assay is powerful in searching for transcription-targeted
lead compounds for treating cancer.
RESULTS
Bicistronic Co-expression of a Reporter Gene with an
Endogenous Gene via IRES
Given the limitations of reporter assays discussed above, we
sought to develop a reliable reporter assay whereby the reporter
gene expression would closely mimic endogenous gene expres-
sion under chemical treatments. Our strategy is to insert the
FLuc gene led by an internal ribosome entry site (IRES) into a
genomic site immediately downstream of the coding region of
an endogenous gene (e.g., EIF4E) (Figure 1). We reasoned that
IRES could allow expression of a single transcript comprising958 Chemistry & Biology 22, 957–964, July 23, 2015 ª2015 Elsevier Lthe reporter gene and the endogenous gene under the control
of the endogenous gene promoter, the distal cis-regulatory ele-
ments, and the native chromatin environment (Figure 1), thereby
yielding a reliable screening assay faithfully reproducing re-
sponses of the endogenous gene to chemical treatments.
We chose to knock the IRES-FLuc DNA into the native EIF4E
gene locus, given that eIF4E-targeted drugs are highly desirable
for cancer treatments (Bitterman and Polunovsky, 2012). We
took a two-step strategy to attain this goal. We first employed
the emerging CRISPR-Cas9 genome-editing tool (Mali et al.,
2013) to insert a fusion selection gene (tk-ble) into a site between
the stop codon (TAA) and the polyadenylation sites of the EIF4E
gene, and then replaced the selection gene with the FLuc gene
through Flp-mediated cassette exchange (RMCE) (Baer and
Bode, 2001) (Figure 2A). The tk-ble fusion gene confers Zeocin
resistance and ganciclovir (GCV) toxicity and thus, respectively,
allows for positive selection for EIF4E-targeting and negative
selection for RMCE events. RMCE can mediate rapid insertions
of other reporter genes into the same targeted locus, thereby
facilitating the development of orthogonal screening assays in
our later experiments (see below).
To insert the selection gene into the EIF4E gene locus, we con-
structed an editing vector that carries the tk-ble gene flanked by
a wild-type (F) and a mutated (F3) FRT fragment (Schlake and
Bode, 1994) (Figure S1A), then cloned the EIF4E homology
arms into the vector to generate a targeting vector, pEIF4E-
Target (Figure 2A). We transfected the targeting vector along
with a single guided RNA (sgRNA), which specifically recognizes
a region downstream of the EIF4E stop codon (Figure 2A), into
human fibrosarcoma HT1080 cells. The sgRNA is able to guide
the Cas9 nuclease to generate a double-strand break (DSB),
thereby facilitating high-efficiency integration of the tk-ble gene
through homology-directed repair (Figure 2A) (Ran et al., 2013).
Indeed, we identified 8 EIF4E-targeted clones from 62 Zeocin-
resistant clones by PCR (Figure 2B). The targeting efficiency
was 12.9%.
We next employed the RMCE technology to generate recom-
binant cells co-expressing FLuc and the endogenous EIF4E
gene as single transcripts. Toward this end, we co-transfected
an EIF4E-targeted clone, E8, with a cassette-exchange vector
carrying the IRES-FLuc cassette flanked by the F and F3 frag-
ments (Figure S2B; Figure 2A), and a Flp-expressing plasmid,
for GCV selection. We found that the tk-ble gene was replaced
by the IRES-FLuc DNA in almost all tested GCV-resistant clones
evidenced by PCR amplification of a DNA fragment composed of
the EIF4E and IRES fragments (Figure 2C). Northern blotting as-
says detected three mRNA bands that were hybridized to both
EIF4E and FLuc probes (Figure 2D, lanes 3 and 6, arrows),
demonstrating that the FLuc gene was expressed as bicistronic
transcripts fused to the EIF4E mRNA in the recombinant cells.
The multiple double-hybridized bands might be generated from
fusion of the FLuc mRNA to different EIF4E splice variants.
Indeed, the EIF4E gene was transcribed as several mRNAs
shown in lane 1 of Figure 2D. By contrast, immunoblotting
assays showed that the FLuc gene was not expressed as a
protein fused to eIF4E (Figure 2E, lane 3). Whereas these
recombinant cells expressed a high level of FLuc (Figure 2F),
their responses to a small molecule (NSC607097) capable of
decreasing EIF4E expression (see below) were comparable.td All rights reserved
Figure 2. Genome Editing by CRISPR-Cas9
Followed by RMCE Generates Cells
Harboring a Reporter Gene in the Endoge-
nous EIF4E Locus
(A) Schematic showing the two-step strategy for
inserting the IRES-FLuc cassette into the EIF4E
gene locus through CRISPR-Cas9 and RMCE.
DSB, DNA double-strand break (indicated by
red arrow); F and F3, wild-type and mutant FRT
sites; LA, left homology arm; pA, polyadenylation
signal; PAM, protospacer adjacent motif; RA, right
homology arm; sgEIF4E, EIF4E-specific sgRNA;
TAA, the stop codon.
(B) Identification of Zeocin-resistant clones car-
rying the tk-ble gene in the targeted EIF4E locus.
Genomic DNAs from resistant clones were sub-
jected to PCR using a primer pair RA-F and RA-R
indicated in (A). Positive clones were expected to
generate a 1.5-kb fragment.
(C) The tk-ble genewas replaced by the IRES-FLuc
cassette in E8-FLuc clones confirmed by PCR. The
primers are indicated in (A). The E8 clone carrying
the tk-ble gene in the targeted EIF4E locus was
chosen for RMCE.
(D) Northern blotting confirmed co-expression of
the FLuc gene and the endogenous EIF4E gene as
single transcripts. Arrows indicate the fused, bi-
cistronic transcripts.
(E) Immunoblotting detected the eIF4E protein. No
fusion of eIF4E to FLuc was found in F8-FLuc cells.
(F) FLuc was highly expressed in recombinant
cells. Clones were lysed for firefly luciferase
activity assays. The FLuc expression level was
comparable among clones.
(G) E8-Fluc clones exhibited responses similar to
those of chemical treatments. The indicated
clones were treated with 2.5 mM NSC607097 for
16 hr for luciferase activity assays.
See also Figure S1.Therefore, we developed a method allowing for highly efficient
generation of recombinant cells expressing a reporter gene un-
der the control of the authentic regulatory mechanism for endog-
enous EIF4E gene expression.
Bicistronic Reporters Yield Screens with a Decreased
False Hit Rate
We reasoned that reporter genes expressed under this condition
would better mimic chemical responses of endogenous genes,
and accordingly that chemical screening based on these recom-
binant cells would yield fewer false hits with improved success
rates. To test this, we treated one of these recombinant cells
(E8-FLuc) with4,800 small molecules from the National Cancer
Institute and a commercial (Chembridge) chemical library
(Figure 3A). We were interested in identifying compounds that
decrease EIF4E expression, as they could be further developed
into agents for treating cancer overexpressing eIF4E. The Z0 fac-
tor of the reporter assay equaled 0.67 (Figure S2A), indicating its
suitability for HTS. As a comparison, we also generated cells car-
rying a FLuc gene driven by a cloned EIF4E promoter (1,512
to 1) in a defined, foreign genomic location (F55-pEIF4E-luc)
(Figure 3A) using a previously developed Flp-based strategy
(Figure S2B) (Nair et al., 2008), and subjected the cells to HTS
similarly. We identified 11 hits from the E8-FLuc-based screenChemistry & Biology 22,and 28 hits from the screen using the F55-pEIF4E-luc cells
(Figure 3B; Table S1); 10 compounds were found to decrease
the firefly luciferase activity in both assays (Figure 3C). We
carried out qRT-PCR to validate these hits, and found that six
hits from the E8-FLuc screen were true positives that indeed
decreased EIF4E expression in cancer cells (Figure 3D; Fig-
ure S3A). These hits decreased the expression of the bicistronic
FLuc reporter inaconcentration-dependentmanner (FigureS3B),
and these effects were unlikely to be caused by cytotoxicity
(Figure S3C). Similar effects were also observed in another inde-
pendent clone (F89-FLuc) carrying the same bicistronic reporter
(Figure S3B). Previously, these compounds were found to have
distinct biological activities, including transcription inhibition
(NSC607097 and NSC146109) (Chau et al., 2005; Wang and
Yan, 2011), direct DNA (NSC71795) (Stiborova et al., 2001) or
protein binding (NSC607097 and NSC255109) (Schulte and
Neckers, 1998; Kahsai et al., 2006), metal chelation (NSC86372)
(Burnett et al., 2003), and protein kinase inhibition (NSC56346)
(Gschwendt et al., 1994) (Table S2). Interestingly, in one of our
early studies we demonstrated that NSC146109 inhibits tran-
scription of another cancer-causing gene, MDMX (Wang and
Yan, 2011), suggesting that EI4E and MDMX might share a
common mechanism for transcriptional regulation. Of note, it
is unlikely that these compounds are pan-assay interference957–964, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 959
Figure 3. A Drug Screen Using the
Bicistronic In Situ Reporter Assays Iden-
tifies EIF4E Inhibitors with a Significantly
Reduced False-Positive Rate
(A) Schematic showing the screening strategy.
A random E8-FLuc clone and a clone (F55-
pEIF4E-luc) carrying a 1.5-kb EIF4E promoter in
a permissive genomic site were treated with library
chemicals in microplates for luciferase activity
assays.
(B) The results of E8-FLuc-based screen (red) and
F55-pEIF4E-luc-based screen (blue). Recombinant
cells in 96-well plates were treated with 4,800
compounds (2.5 mM) for 16 hr, then lysed for firefly
luciferase activity assays. The relative luciferase
activities were converted into logarithm values (bi-
nary logarithm, i.e., log2) and plotted for each
compound. The cutoff values set for positives
are ±0.5849, i.e., either decrease to at least 66.7%
or increase to at least 150% of the DMSO group,
andare indicatedby thedotted lines.Chemicals that
decreased the luciferase activity due to cytotoxicity
were identifiedbyMTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assays, and
excluded from further investigation in this study.
These chemicals were not shown in this graph.
(C) Venn diagram showing the numbers of hits (i.e., decreasing the FLuc activity) from the screens using E8-FLuc or F55-pEIF4E-luc cells.
(D) qRT-PCR validation of the hits from two screens. The dotted lines indicate the cutoff (<0.667) for positives. Error bars represent SD for three replicate
measurements.
(E) Venn diagram showing the validated EIF4E inhibitors.
See also Figures S2 and S3.compounds (Baell and Holloway, 2010; Baell andWalters, 2014),
as we did not identify these compounds, except NSC146109, as
positivehits in ourprevious screenusingaFLuc reporter drivenby
a cloned MDMX promoter (Wang et al., 2011). Indeed, we
confirmed that one of these hits, NSC607097, decreased EIF4E
expression in several other human cancer cells (Figure S3D),
and that it was not a general transcription inhibitor as it did not
alter the MDMX promoter activity (Figure S3E). Of these
compounds, five were also identified as positive in the F55-
pEIF4E-luc-based screen (Figure 3E). However, NSC56346,
one validated EIF4E inhibitor, was missed in the latter screen us-
ing the cloned, transgenicEIF4Epromoter (Figure 3E), arguing for
the notion that cis-regulatory elements modulated by some
chemicals might be omitted from cloned promoters. Therefore,
the false-positive rate of the screen based on the in situ reporter
was 45.4%, which was significantly lower than that (82.1%) of
the F55-pEIF4E-luc-based screen (p = 0.044, Fisher’s exact
test). Our results thus demonstrated that the screening assay
based on the bicistronic in situ reporter was more efficient.
Orthogonal Assays Readily Developed through RMCE
Identifies False Hits Targeting Luciferase
However, up to 45% of the hits from the new screening assay
were still false positives. These artifacts might be caused by
small molecules that interfere with the reaction catalyzed by
FLuc, or affect the stability of the FLuc protein/mRNA (Feng
et al., 2007; Auld et al., 2008). Indeed, a recent study suggests
that more than 40% of positive hits from FLuc-based assays
could be FLuc inhibitors, and many of these FLuc inhibitors
counterintuitively increase FLuc activity (Thorne et al., 2010).
An approach to identify these false positives is to counter-screen960 Chemistry & Biology 22, 957–964, July 23, 2015 ª2015 Elsevier Lthem using an orthogonal assay that measures the activity of a
reporter distinct from FLuc (e.g., Renilla luciferase or RLuc)
(Auld et al., 2008; Thorne et al., 2010). To test this strategy, we
employed RMCE (Figure 4A) to generate recombinant cells
carrying the RLuc gene in the same genomic location as the
E8-FLuc cells by transfecting E8 cells with a new cassette-ex-
change construct carrying an IRES-RLuc cassette (Figure S2C).
The new recombinant cells (E8-RLuc) verified by PCR (Figure 4B)
responded to treatments with the validated EIF4E inhibitor
NSC607097 in a manner similar to that of E8-FLuc cells (Fig-
ure 4C). Interestingly, none of the tested compounds that
increased the FLuc activity in the primary screen altered the
RLuc activity in the new recombinant cells (Figure 4D).Moreover,
whereas the six validated EIF4E inhibitors decreased the RLuc
activity as expected, four of the five false positives identified in
the primary screen did not alter the RLuc activity (Figure 4D).
The only false hit that was missed by the orthogonal screening
assay, NSC321239, was found to directly inhibit both the FLuc
and the RLuc activity (Figure 4E). Thus, an orthogonal screening
assay using a RLuc reporter gene engineered to reside in the
same genomic location as FLuc could identify and exclude a
majority of false positives. The RMCE technology employed in
our cell-engineering strategy allows for fast, convenient devel-
opment of such an orthogonal screening assay. Overall, the
screens based on our new reporter assays yielded a false-posi-
tive rate of lower than 10%.
DISCUSSION
Targeting aberrant expression of cancer-driving genes using
small molecules is a promising anti-cancer strategy (Yan andtd All rights reserved
Figure 4. An Orthogonal Screening Assay
Based on RLuc Inserted in the Same EIF4E
Locus Identifies a Majority of False Hits
(A) Diagram showing that RMCE mediates rapid
insertion of the RLuc gene into the same genomic
location as FLuc.
(B) PCR results confirmed the replacement of the
tk-ble gene with RLuc in E8-RLuc cells.
(C) E8-RLuc cells responded to chemical treat-
ments in the same way as E8-FLuc cells.
Cells were treated with NSC607097 for 16 hr for
luciferase activity assays.
(D) Effects of primary hits (including those com-
pounds that increased the FLuc activity by at least
1-fold) on EIF4E mRNA level and reporter gene
activity. The only false hit (NSC321239) that could
not be identified by the orthogonal assay is indi-
cated by the red arrow. The red dotted lines indi-
cate the cutoff value.
(E) NSC321239 is an inhibitor of both FLuc and
RLuc. Lysates from cells expressing FLuc or RLuc
were incubated with 2.5 mM NSC321239, or
Pifithrin-a (a known FLuc inhibitor), on ice before
assaying for FLuc or RLuc activity. Error bars
represent SD for three replicate measurements.Paul, 2013), yet its success is limited due to lack of reliable HTS
assays. In this report, we present a proof of principle for a versa-
tile strategy that can be employed to engineer cultured cells and
allow them to express reporter genes under control of the native
mechanism for regulation of endogenous gene expression,
thereby yielding screening assays closely mimicking responses
of endogenous genes to chemical treatments. This strategy
also allows for convenient insertions of different reporter genes
into the same genomic locations, and therefore facilitates rapid
development of orthogonal screening assays for identification
of false positives generated from primary screens. We demon-
strated that these bicistronic in situ reporter assays are powerful
in searching for therapeutic agents targeting abnormal gene
expression in cancer, with high confidence and improved suc-
cess rates.
Previously, a drug-screening platform based on a FLuc gene
knocked into the genomic site immediately downstream of the
Nanog promoter was developed for identifying small molecules
that can increase Nanog expression (Lyssiotis et al., 2009).
Although this knock-in reporter assay was successful in identi-
fying compounds that functionally replace KLF4 to induce plurip-
otent stem cells, its development utilizes embryonic stem cells
and requires production of genetically engineered mice (Lyssio-
tis et al., 2009). Moreover, the platform has limitations in that
(1) the endogenous Nanog gene was disrupted, and that (2) it
is highly likely that the exogenous DNA (i.e., FLuc-pA) proximal
to TSS influences transcription initiation and/or the interplay be-
tween the promoter and distal cis-acting elements essential for
gene expression (Levine et al., 2014). A recent reporter system
wherein a luciferase gene was inserted into the CCND1 exon 1Chemistry & Biology 22, 957–964, July 23, 2015by a zinc finger nuclease (ZFN) has the
same limitations, although the reporter
gene was expected to be co-expressed
with CCND1 through translational skip-ping (Samsonov et al., 2013). On the contrary, knocking reporter
genes into 30-UTRs, which are often distant from TSS, maintains
the integrity of endogenous genes, thereby minimizing distur-
bances of their expression by genome editing. Indeed, we found
that the insertion of IRES-FLuc into the EIF4E locus did not alter
eIF4E expression in the recombinant cells (Figure 2E). Therefore,
bicistronic co-expression of reporter genes appears to be more
advantageous over currently available assays for drug screening.
We chose IRES rather than 2A peptides for reporter co-
expression because the latter, although smaller in size, add extra
residues to endogenous proteins, whereas the 2A peptide se-
quences need to be seamlessly fused with the EIF4E and FLuc
coding sequence (de Felipe et al., 2006). Although IRES-depen-
dent translation of reporter genes might not be as efficient as
that of endogenous genes (Martin et al., 2006), bioluminescent
reporter assays are highly sensitive and thus would allow for
readily measuring alterations in reporter gene expression upon
chemical treatments. Indeed, the luminescence reading reached
to five digits in our assays (Figure 2F).
Genome editing, including inserting exogenous DNA into
endognous gene loci in cultured cells, can be achieved through
homologous recombination mediated by recombinant adenoas-
sociated viruses (rAAV) or artificial gene-specific nucleases
(e.g., ZFN and TALEN) (Khan et al., 2011; Urnov et al., 2010;
Bogdanove and Voytas, 2011). However, these approaches are
either laborious (e.g., ZFN and TALEN), or low in efficiency
(e.g., rAAV). Because of its simplicity in use and high efficiency
in gene targeting, the CRISPR-Cas9 technology has quickly
emerged as a powerful tool for genome editing (Mali et al., 2013;
Ran et al., 2013). Indeed, we readily obtained 8 EIF4E-targetedª2015 Elsevier Ltd All rights reserved 961
clones in a single targeting experiment. In contrast, using a rAAV-
based approach we only identified one positive clone from 95
Zeocin-resistant clones (data not shown).Of note, theeditingvec-
tor that we developed contains the backbone of a rAAV vector
(see Experimental Procedures) and thus can also be packed
into viral particles for rAAV-mediated targeting. It is worth noting
that the CRISPR-Cas9 technology currently suffers from a limita-
tion in that the Cas9 nuclease may generate DSBs at multiple un-
intended genomic sites owing to short recognition sequences of
guided RNAs, which can lead to off-target editing.Whereas small
insertions or deletions (indels) are produced by non-homologous
end joining atDSBs (Ranet al., 2013), homologous recombination
mediated by the EIF4E homology arms could efficiently prevent
insertions of the selection gene (tk-ble) into off-target sites.
Indeed, while off-target integration events could be readily identi-
fied and excluded by PCR screening, our recombinant cells
expressed the FLuc gene as single transcripts fused with EIF4E
(Figure 2D), indicating that the reporter gene was only inserted
into the intended genomic site. Probable generation of indels in
other genomic sites can interfere with gene functions, but might
be least problematic for HTS studies, as the possibility that indels
alter pathways regulatory for expression of the genes of interest is
remote.
We also employed RMCE to develop our in situ reporter
assays. This technology utilizes the yeast Flp recombinase to
mediate cassette exchange through homologous recombination
between two FRT pairs (Schlake and Bode, 1994; Baer and
Bode, 2001), resulting in rapid insertion of any reporter genes
into a FRT-flanked genomic site (Figure 2A). It is therefore
possible to readily re-engineer recombinant cells by replacing
one reporter gene with another, generating orthogonal assays
that are critical to the success of reporter-based drug screening
(Cheng and Inglese, 2012). RMCE also allows for convenient
generation of reporter cells carrying improved reporters, such
as codon-optimized, destabilized, or secreted luciferases, and
thus provides maximal flexibility for HTS applications. As
RMCE excises the selection gene from the target site (Figure 2A),
it is also possible to engineer cells multiple times to insert two or
more reporter genes into distinct gene loci via different FRT
combinations (Baer and Bode, 2001) and, accordingly, multiplex
reporter-based HTS assays for highly effective drug discovery.
During the preparation of this article, a TALEN-based genome-
editing strategy was reported to generate HTS assays wherein
a luciferase gene was engineered into the 30-UTR and co-ex-
pressed with the endogenous PMP22 gene through a 2A peptide
(Inglese et al., 2014). Interestingly, this most recent research also
identified a compound that had escaped from a previous screen
based on a randomly integrated reporter (Inglese et al., 2014).
Therefore, HTS assays built on co-expressed in situ reporters
appear to be more reliable for searching for small molecules to
target transcription.
SIGNIFICANCE
The success of transcription-targeted therapy is hindered
by lack of reliable reporter gene assays for high-throughput
drug screening. Traditional assays do not faithfully repro-
duce chemical responses of endogenous genes as they
are based on cloned, transgenic promoters, which often962 Chemistry & Biology 22, 957–964, July 23, 2015 ª2015 Elsevier Lcontain incomplete cis-acting elements and are also
affected by flanking epigenetic factors. The novel genome-
editing strategy presented herein provides a rapid and
efficient means to generate recombinant cells carrying re-
porter genes bicistronically co-expressed with endogenous
genes under the control of native transcriptional regulatory
machineries, yielding a powerful drug-screening platform
for discovering lead compounds targeting aberrant gene
transcription in cancer and other human diseases.
EXPERIMENTAL PROCEDURES
Vector Construction
Standard molecular cloning methods were used for vector construction. To
construct the editing vector (pAAV-F-TKZeo-F3), we first PCR amplified the
tk-ble fusion gene from pORF9-HSV-tk:Shble (InvivoGen), then cloned it to
pAAV-TK-Acceptor (Kim et al., 2008) after excising the loxP-Neo-loxP
cassette from the latter plasmid. Oligonucleotides containing the wild-type
FRT site and the mutated F3-FRT site (Schlake and Bode, 1994) were then
inserted into the plasmid at the SpeI/BamHI site and the SacII/AvrII site,
respectively. To construct the EIF4E-targeting vector, the left and right homol-
ogy arms were amplified by PCR and respectively cloned into the AscI/SpeI
site and the EcoRI/AvrII site of the editing vector. To construct the cassette-ex-
change vector (pF-luc2pA-F3), the IRES fragment was amplified from p414
(Liao et al., 2011) by PCR and cloned into pGL4.10 (Promega) (SacI/XhoI sites),
followed by addition of the F and F3 fragments to sites flanking the luc2 gene
(SpeI/SacI and BamHI/SalI sites, respectively). The luc2 gene in this plasmid
was then replaced with an RLuc gene amplified from pRL-TK (Promega),
generating the cassette-exchange vector for RLuc (pF-RLucpA-F3). Table
S3 lists the sequences of PCR primers used for cloning or other applications
described below.
CRISPR-Cas9-Based Genome Editing
The CRISPR-Cas9 genome-editing tool developed by the Zhang laboratory
(Ran et al., 2013) was employed to insert the tk-ble gene into the EIF4E locus.
We first identified an sgRNA specifically targeted region (50-GCGTCAAG
CAATCGAGATT-30) immediately downstream of the stop codon of the EIF4E
gene, then synthesized and ligated oligonucleotides containing this sequence
to the pSpCa9(BB)-2A-Puro plasmid (Ran et al., 2013). HT1080 cells (93 105)
in a 60-mm dish were transfected with 2 mg of the sgRNA-expressing plasmid
and 4 mg of the EIF4E targeting vector using Lipofectamine 2000 (Invitrogen),
then trypsinized and re-plated into three 100-mm dishes 2 days later. After
selection with 0.5 mg/ml puromycin for 3 days, transfected cells were cultured
in Zeocin-containing (175 mg/ml) medium until single clones grew up. These
resistant clones were plated in 96-well plates and lysed in 50 ml of a buffer con-
taining 10 mM Tris-HCl (pH 7.5), 10 mM EDTA, 10 mM NaCl, 0.5% SDS, and
1 mg/ml proteinase K at 37C overnight. Genomic DNAs were then precipi-
tated by adding 100 ml of cold NaCl/ethanol mixture (0.075 M NaCl), washed
with 75% ethanol, air-dried, and dissolved in 35 ml of TE buffer for PCR
screening for targeting events using the primers listed in Table S3.
Flp-Mediated Cassette Exchange
E8 (HT1080) cells in a 60-mmdish were transfected with 4 mg of pCAGGS-Flpe
(Gene Bridges) and 2 mg of pF-luc2pA-F3 or pF-RLucpA-F3, for 2 days, then
re-plated into 100-mm dishes at a density of 5 3 104 per dish and cultured
in a medium containing 7.5 mg/ml of GCV for 2–3 weeks. Resistant clones
were expanded, and lysed for luciferase activity assays. Genomic DNAs
were also prepared as described above and subjected to PCR to confirm
the replacement of the tk-ble gene.
Northern Blotting and qRT-PCR
Total RNA was prepared using the Trizol Reagent (Life Technologies). For
northern blotting, denatured RNA samples were resolved in 1% agarose,
transferred to Hybond N+ nylon membranes, and hybridized with [32P]EIF4E
fragment amplified by PCR. After extensive washes, the membrane was wrap-
ped with plastic wrap and subjected to autography. The EIF4E probe was thentd All rights reserved
stripped by incubating the membrane with boiled 0.1% SDS for 1 hr, and
re-hybridized with [32P]FLuc gene fragment for detection of FLuc mRNA. For
qRT-PCR, total RNA (1 mg) was reverse transcribed using the DyNAmo
cDNA Synthesis Kit. 1 ml of cDNA was then subjected to qRT-PCR assay in
a total of 20 ml using the SYBR Green PCR reagent (Qiagen) and the StepOne
Plus Real-time PCR system as described previously (Yan andBoyd, 2006). The
EIF4E mRNA level was normalized to the glyceraldehyde-3-phosphate dehy-
drogenase mRNA level.
Chemical Library Screening
Screening was carried out as described elsewhere (Nair et al., 2008). In brief,
cells (1.2 3 104/well in 100 ml of medium) in 96-well plates were treated with
2.5 mM chemicals (0.5 ml) from the NCI Diversity Set, the NCI Natural Products
set, and a commercial (Chembridge) chemical library, for 16 hr, then washed
with PBS using the Aquamax Plate Washer (Molecular Devices). In each plate,
the non-response/negative control DMSO (0.5 ml) was added into wells A1, C1,
E1, G1, B12, D12, and F12, while cells in wells B1, D1, F1, H1, A12, C12, E12,
and G12 were treated with the positive control actinomycin D (1 mM) or
NSC607097 (2.5 mM). After the cells were lysed in 80 ml of lysis buffer (1%
Triton X-100, 25 mM Gly-Gly [pH 7.8], 15 mM MgSO4, and 4 mM EDTA) at
room temperature for 20 min, 10 ml of cell lysates was dispensed into white
96-well plates andmixed with 50 ml of luciferase substrates (Promega) for lumi-
nescence reading using the SpectraMax L luminometer (Molecular Devices).
The average luminescence intensity of DMSO-treated wells in each plate
was used to calculate the relative reporter activity (relative luminescence) for
each well treated with tested chemicals.
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